Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Philip Morris (PM): Still smokin'


Bookmark and Share

 "During volatile and uncertain markets, a good defensive stock can provide much better protection and profits than moving into money markets or Treasuries," explains Louis Basenese.

The contributing analyst to The Oxford Club explains, "My favorite defensive pick right now is Philip Morris (NYSE: PM) – the world's second-largest cigarette manufacturer." Here's his bullish outlook.

"Despite fears that the economic recovery is on shaky ground, I would caution you against adopting a bunker mentality.

"First, we get paid more than Treasuries to own shares. Thanks to a recent dividend hike, Philip Morris now yields 4.8%, almost one full percentage point better than the 30-year bond. And a steady stream of income goes a long way to help smooth out any market volatility.

"To be fair, the dividend isn't backed by the full faith and credit of the U.S. government. But we don't need any such insurance. Demand for tobacco products is forever steady. In fact, Citi Investment Research proved the last two recessions 'had no material effect on cigarette demand.' 

Advertisement
Banner

"The latest quarterly results indicate this recession will be no different. Philip Morris sold exactly the same amount of cigarettes (223.1 million) in the second quarter of 2009 as it did in the second quarter of 2008.

"And such predictable demand provides more than enough cash ($7.41 billion) to fund the annual dividend ($4.5 billion). Throw in high barriers to entry, reasonable debt levels and no risk of domestic litigation and the dividend is just as safe and reliable as Uncle Sam's.

"Of course, the reasons to own Philip Morris extend beyond the security of an income stream. The stock also provides a hedge against a declining dollar.

"Recall, 100% of sales come from overseas. Even better, it offers strong prospects for appreciation thanks to its exposure to emerging markets, which generates more than 60% of the company's sales.

"Tobacco sales in emerging markets are increasing modestly compared to declining volumes in developed markets. And Philip Morris is uniquely positioned to capture the lion's share of this growth. It owns seven of the leading 15 international brands, including the hands down leader, Marlboro.

"The fact that management recently raised guidance only underscores the growth opportunities. And as we know, when a company consistently increases earnings, share prices tend to come along for the ride.

"Philip Morris is no exception. After last quarter's better than expected results, shares jumped almost 8% in two days.We expect a similar reaction when the company reports results on October 22.

"The stock is up nicely, about 40%, since our recommendation in February. But that doesn't preclude it from running higher still.

"Not when shares trade so cheaply, at roughly a 20% discount to the average stock in the S&P 500. I'm convinced this defensive pick will prove to be the perfect offense during these uncertain times."


Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary